In breast cancer, loss of SLIT/ROBO signaling may decrease the phosphorylation of downstream CXCL12/CXCR4 molecules, increase GSK-3β phosphorylation, and influence the expression and distribution of β-catenin. The gene discussed is CXCR4; the disease is breast cancer.